Azitra Inc (AZTR) Stock Price, Quote & News

Company Profile

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically m...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 646 6446

Website: azitrainc.com

Address:

21 Business Park Drive, Branford, United States

Schizoo Aug. 3 at 2:04 PM

$AZTR in for a swing.

0 · Reply

Olivia_Strickland Aug. 3 at 12:47 PM

$AZTR grinding down 5.6% premarket at 0.1253, 11M shares already. sub-penny price and that kind of volume, these thin moves can get ugly fast. feeling like I'm missing something here, someone fill me in on my morning watchlist: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=aztr-pm-dn-watch&utm_term=scanner&s=AZTR

0 · Reply

Olivia_Strickland Aug. 3 at 10:35 AM

$AZTR down 8.9% premarket at 0.1193, 10M vol on a sub-penny name. that's a lot of shares for something trading this thin. someone explain this tape to me live premarket tape: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=aztr-pm-dn-tape&utm_term=scanner&s=AZTR

0 · Reply

Olivia_Strickland Aug. 3 at 10:03 AM

$AZTR gapping up 24% premarket at 0.1648, 5M shares already. sub-dollar moves this early can swing either way once the bell hits. what level you guys watching here? premarket gap, live tape: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=aztr-pm-up-gap&utm_term=scanner&s=AZTR

0 · Reply

dln101 Jul. 31 at 6:47 PM

$MGRX which bio penny gonna be next to 🚀 $AZTR or $CLGN 🤔💪📈

0 · Reply

theflynews Jul. 29 at 6:21 PM

Meet Azitra: Fly Exclusive with CEO Francisco Salva - $AZTR - https://thefly.com/AZTR

0 · Reply

Aleexandder Jul. 25 at 12:17 AM

$AZTR Develops genetically engineered skin bacteria and protein-based therapies designed to treat dermatologic diseases. Its approach aims to use the skin microbiome as a therapeutic delivery platform!!

0 · Reply

AVCTQ Jul. 24 at 9:09 AM

$AZTR great opportunity with $RECT Read and take a look.

0 · Reply

MikiTrader Jul. 18 at 5:55 PM

$AZTR I told you it was heavy much more than you think

0 · Reply

StockHolms Jul. 17 at 4:46 PM

$AZTR Holding up nicely for a Friday …. Let’s get some positive news. Send it !!

0 · Reply

Meet Azitra: Fly Exclusive with CEO Francisco Salva

2026-07-29T18:05:54.000Z - 5 days ago

Azitra building multi market microbial engineering platform, CEO says

2026-07-29T18:05:50.000Z - 5 days ago

Azitra says Phase 1/2 ATR 04 trial remains on track for topline data this year

2026-07-29T18:05:45.000Z - 5 days ago

CEO says breadth of Azitra’s platform opens multiple attractive markets

2026-07-15T14:30:18.000Z - 19 days ago

Azitra announces results from two ex vivo human skin tissue studies

Jul 15, 2026, 10:10 AM EDT - 19 days ago

Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity

Jun 17, 2026, 8:00 AM EDT - 6 weeks ago

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

Jun 4, 2026, 4:05 PM EDT - 2 months ago

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

Jun 4, 2026, 8:00 AM EDT - 2 months ago

Azitra Proxy statement: Proxy filing

May 27, 2026, 4:30 PM EDT - 2 months ago

Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting

May 27, 2026, 8:00 AM EDT - 2 months ago

Azitra Proxy statement: Proxy filing

2026-05-21T21:00:49.000Z - 2 months ago

Azitra files to sell 255.7M shares of common stock for holders

May 21, 2026, 8:00 AM EDT - 2 months ago

Azitra Registration statement: Registration filing

May 13, 2026, 8:30 AM EDT - 2 months ago

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates

May 13, 2026, 8:00 AM EDT - 2 months ago

Azitra Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Azitra Earnings release: Q1 2026

May 8, 2026, 8:00 AM EDT - 3 months ago

Azitra Proxy statement: Proxy filing

2026-05-07T06:25:51.000Z - 3 months ago

Azitra granted new U.S. patent protecting ATR-12 program

May 6, 2026, 8:00 AM EDT - 3 months ago

Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Apr 28, 2026, 8:02 AM EDT - 3 months ago

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Azitra Proxy statement: Proxy filing

2026-03-21T00:36:00.000Z - 4 months ago

Why Is Azitra Inc Stock (AZTR) Up Today?

2026-03-19T17:45:16.000Z - 4 months ago

Azitra Inc trading resumes

Mar 19, 2026, 1:13 PM EDT - 4 months ago

Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million

2026-03-19T16:25:35.000Z - 4 months ago

Azitra Inc trading halted, news pending

Mar 13, 2026, 5:15 PM EDT - 5 months ago

Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement

Mar 5, 2026, 4:30 PM EST - 5 months ago

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

Mar 5, 2026, 7:00 AM EST - 5 months ago

Azitra Proxy statement: Proxy filing

Mar 2, 2026, 7:00 AM EST - 5 months ago

Azitra Slides: Corporate presentation

Feb 27, 2026, 5:30 PM EST - 5 months ago

Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates

Feb 27, 2026, 7:00 AM EST - 5 months ago

Azitra Annual report: Q4 2025

Feb 27, 2026, 7:00 AM EST - 5 months ago

Azitra Earnings release: Q4 2025

2026-02-24T13:12:53.000Z - 5 months ago

Azitra adds MD Anderson Cancer Center as site for Phase 1/2 skin rash trial

Feb 24, 2026, 8:00 AM EST - 5 months ago

Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash

Feb 19, 2026, 8:00 AM EST - 5 months ago

Azitra, Inc. to Present at BIO Investment & Growth Summit

Feb 6, 2026, 4:15 PM EST - 6 months ago

Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Feb 6, 2026, 7:00 AM EST - 6 months ago

Azitra Proxy statement: Proxy filing

Jan 7, 2026, 8:00 AM EST - 7 months ago

Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

Jan 2, 2026, 7:00 AM EST - 7 months ago

Azitra Proxy statement: Proxy filing

Dec 23, 2025, 7:00 AM EST - 7 months ago

Azitra Proxy statement: Proxy filing

2025-12-17T21:16:09.000Z - 8 months ago

Azitra says NYSE American approves compliance plan

Dec 17, 2025, 4:10 PM EST - 8 months ago

Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

2025-12-10T21:16:02.000Z - 8 months ago

Azitra files to sell 38.9M shares of common stock for holders

Dec 10, 2025, 7:00 AM EST - 8 months ago

Azitra Registration statement: Registration filing

2025-11-24T14:20:36.000Z - 9 months ago

Azitra prices 4.69M share private placement at 32c per share

Nov 24, 2025, 9:00 AM EST - 9 months ago

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules

Nov 13, 2025, 7:00 AM EST - 9 months ago

Azitra Slides: Corporate presentation

Nov 12, 2025, 5:15 PM EST - 9 months ago

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

Nov 12, 2025, 7:00 AM EST - 9 months ago

Azitra Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 9 months ago

Azitra Earnings release: Q3 2025

2025-11-07T11:10:47.000Z - 9 months ago

Azitra says report of $44M registered direct offering is false

Nov 7, 2025, 6:00 AM EST - 9 months ago

Azitra, Inc. Addresses False Report Regarding Sale of Securities

2025-10-20T12:10:25.000Z - 10 months ago

Azitra to present preclinical progress for its ATR-01 program

Oct 20, 2025, 8:02 AM EDT - 10 months ago

Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris

2025-10-03T20:55:06.000Z - 10 months ago

Azitra receives noncompliance notification from NYSE

Oct 3, 2025, 4:45 PM EDT - 10 months ago

Azitra Receives Notice of Non-Compliance from NYSE American

2025-09-24T12:05:22.000Z - 11 months ago

Azitra price target lowered to $4 from $13.32 at Maxim

Sep 4, 2025, 8:10 AM EDT - 11 months ago

Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 29, 2025, 8:00 AM EDT - 1 year ago

Azitra Registration statement: Registration filing

2025-08-28T01:25:00.000Z - 1 year ago

Azitra Stock (AZTR) Rockets on Clinical Trial Update

Aug 27, 2025, 8:10 AM EDT - 1 year ago

Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

Aug 11, 2025, 4:15 PM EDT - 1 year ago

Azitra, Inc. Announces Reverse Stock Split

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Azitra Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Azitra Earnings release: Q2 2025

Jul 18, 2025, 8:00 AM EDT - 1 year ago

Azitra Registration statement: Registration filing

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Azitra Proxy statement: Proxy filing

Jun 17, 2025, 8:02 AM EDT - 1 year ago

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Jun 10, 2025, 8:33 AM EDT - 1 year ago

Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

May 29, 2025, 8:00 AM EDT - 1 year ago

Azitra Proxy statement: Proxy filing

May 28, 2025, 8:33 AM EDT - 1 year ago

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

May 19, 2025, 8:00 AM EDT - 1 year ago

Azitra Proxy statement: Proxy filing

May 14, 2025, 4:05 PM EDT - 1 year ago

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

May 13, 2025, 5:06 PM EDT - 1 year ago

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

May 13, 2025, 8:00 AM EDT - 1 year ago

Azitra Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Azitra Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Azitra Registration statement: Registration filing

Apr 25, 2025, 8:33 AM EDT - 1 year ago

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Apr 24, 2025, 4:05 PM EDT - 1 year ago

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

Mar 12, 2025, 8:33 AM EDT - 1 year ago

Azitra to Present at Microbiome Times Partnering Forum

Feb 24, 2025, 8:30 AM EST - 1 year ago

Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 7:00 AM EST - 1 year ago

Azitra Annual report: Q4 2024

Feb 24, 2025, 7:00 AM EST - 1 year ago

Azitra Earnings release: Q4 2024

Feb 4, 2025, 2:20 PM EST - 1 year ago

Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

Feb 3, 2025, 9:05 AM EST - 1 year ago

Azitra, Inc. to Present at the BIO CEO & Investor Conference

Jan 27, 2025, 4:05 PM EST - 1 year ago

Azitra, Inc. to Present at The Microcap Conference

Jan 15, 2025, 8:30 AM EST - 1 year ago

Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock

Jan 14, 2025, 4:05 PM EST - 1 year ago

Azitra Announces Proposed Public Offering of Common Stock

Jan 14, 2025, 7:00 AM EST - 1 year ago

Azitra Proxy statement: Proxy filing

Jan 14, 2025, 7:00 AM EST - 1 year ago

Azitra Proxy statement: Proxy filing

Jan 3, 2025, 7:00 AM EST - 1 year ago

Azitra Proxy statement: Proxy filing

Nov 12, 2024, 5:05 PM EST - 1 year ago

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

Nov 12, 2024, 7:00 AM EST - 1 year ago

Azitra Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Azitra Earnings release: Q3 2024

Oct 29, 2024, 9:00 AM EDT - 1 year ago

Azitra to Present at BIO-Europe 2024

Oct 11, 2024, 9:00 AM EDT - 1 year ago

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Azitra Proxy statement: Proxy filing

Sep 24, 2024, 8:00 AM EDT - 2 years ago

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

Sep 18, 2024, 9:00 AM EDT - 2 years ago

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Sep 6, 2024, 4:30 PM EDT - 2 years ago

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 8:30 AM EDT - 2 years ago

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 22, 2024, 9:00 AM EDT - 2 years ago

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Aug 20, 2024, 4:15 PM EDT - 2 years ago

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Aug 12, 2024, 6:23 PM EDT - 2 years ago

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Azitra Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Azitra Earnings release: Q2 2024

Jul 25, 2024, 5:57 PM EDT - 2 years ago

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

Schizoo Aug. 3 at 2:04 PM

$AZTR in for a swing.

0 · Reply

Olivia_Strickland Aug. 3 at 12:47 PM

0 · Reply

Olivia_Strickland Aug. 3 at 10:35 AM

0 · Reply

Olivia_Strickland Aug. 3 at 10:03 AM

0 · Reply

dln101 Jul. 31 at 6:47 PM

$MGRX which bio penny gonna be next to 🚀 $AZTR or $CLGN 🤔💪📈

0 · Reply

theflynews Jul. 29 at 6:21 PM

Meet Azitra: Fly Exclusive with CEO Francisco Salva - $AZTR - https://thefly.com/AZTR

0 · Reply

Aleexandder Jul. 25 at 12:17 AM

0 · Reply

AVCTQ Jul. 24 at 9:09 AM

$AZTR great opportunity with $RECT Read and take a look.

0 · Reply

MikiTrader Jul. 18 at 5:55 PM

$AZTR I told you it was heavy much more than you think

0 · Reply

StockHolms Jul. 17 at 4:46 PM

$AZTR Holding up nicely for a Friday …. Let’s get some positive news. Send it !!

0 · Reply

BigGreenCandle Jul. 17 at 4:05 PM

$AZTR Nano Cap with Institutional ownership and adding. What's the deal here? Any split coming?

0 · Reply

dawsondesign Jul. 15 at 5:53 PM

$AZTR big cup handle on the 30min

0 · Reply

dawsondesign Jul. 15 at 5:52 PM

$AZTR got a .1358 high to break, pop it from here

0 · Reply

focafoca99 Jul. 15 at 5:16 PM

$AZTR demonstrates promising ex vivo anti-wrinkle results for its ATR-COSF program.

0 · Reply

dawsondesign Jul. 15 at 4:51 PM

$AZTR

0 · Reply

AVCTQ Jul. 15 at 2:32 PM

$AZTR hot 🔥

0 · Reply

AVCTQ Jul. 15 at 2:28 PM

$AZTR great potential, going to $3 in the next 3 months, make a profit and sell before the result.

0 · Reply

Bunkstonks Jul. 2 at 1:44 PM

$AZTR today’s the day

2 · Reply

N0St0pL0ss Jun. 29 at 9:53 PM

$AZTR

0 · Reply

OG80 Jun. 29 at 5:26 PM

$AZTR Estimates?

0 · Reply

Olivia_Strickland Jun. 29 at 8:41 AM

$AZTR creeping up 5% premarket on right under 2M shares. these sub-dollar names love to gap then chop sideways once RTH opens and the float starts churning. no read on the why yet. who else has eyes on this one? premarket chart here: https://tapeboard.com/go/st/research/AZTR?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=aztr-pm-up-chart&utm_term=research

0 · Reply

ZeebraNotZebra Jun. 29 at 4:28 AM

$AZTR this one just hit the overnight ceiling, and had an overnight run of +15%. What's the new here?

1 · Reply

Market Cap	2.15M
Revenue (ttm)	0.00
Net Income (ttm)	-10.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	14,100,100
Avg Vol	14,564,260
Day's Range	N/A - N/A
Shares Out	16.19M
Stochastic %K	35%
Beta	-1.21
Analysts	Strong Sell
Price Target	$0.78